...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetic medicine: A journal of the British Diabetic Association >Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.
【24h】

Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.

机译：罗格列酮治疗2型糖尿病患者中ABCA1变异体对动脉粥样硬化血脂异常的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: To investigate the effect of two common ATP-binding cassette transporter 1 (ABCA1) polymorphisms (rs4149263 and rs2020927) on atherogenic dyslipidaemia in Korean Type 2 diabetic patients who were treated with rosiglitazone. PATIENTS AND METHODS: Two hundred and fifty-six patients with Type 2 diabetes who had never previously received peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists or lipid-lowering treatment were treated with 4 mg of rosiglitazone daily for 12 weeks without any adjustment to their glucose-lowering regimen. The primary outcome was the change in atherogenic index of plasma (AIP), calculated as log [triglyceride (mmol/l)/high-density lipoprotein cholesterol (mmol/l)], before and after rosiglitazone treatment. The effect of rosiglitazone on the change in AIP was compared across the ABCA1 single nucleotide polymorphisms (SNPs) rs41429263 and rs2020927. RESULTS: Before adjustment, the change in AIP at 12 weeks was significantly different across the rs4149263 genotypes [median (interquartile range): -0.05 (-0.21, 0.09) for TT; 0.02 (-0.09, 0.17) for TC; and 0.11 (0.03, 0.25) for CC; P = 0.003], but not across the rs2020927 [-0.04 (-0.18, 0.10) for TT; 0.03 (-0.17, 0.15) for TC; and -0.03 (-0.13, 0.10) for CC; P = 0.401]. After controlling for age, gender and duration of diabetes, the presence of the C-allele was significantly associated with an increase in AIP by 0.13 [95% confidence interval (CI), 0.04-0.21; P = 0.003]. This association did not change significantly when body mass index and pretreatment metabolic parameters were additionally controlled for (the change in AIP: 0.14; 95% CI, 0.04-0.24; P = 0.007). CONCLUSIONS: The ABCA1 SNP rs4149263 may be associated with the change in atherogenic lipid profile in Type 2 diabetes treated with rosiglitazone.
机译：目的：研究两种常见的ATP结合盒转运蛋白1（ABCA1）多态性（rs4149263和rs2020927）对用罗格列酮治疗的韩国2型糖尿病患者的动脉粥样硬化性血脂异常的影响。患者和方法：256例以前从未接受过氧化物酶体增殖物激活受体伽玛（PPAR-γ）激动剂或降脂治疗的2型糖尿病患者，每天接受4毫克罗格列酮治疗，持续12周，而未进行任何治疗调整他们的降糖方案。主要结果是罗格列酮治疗前后血浆的动脉粥样硬化指数（AIP）的变化，以log [甘油三酸酯（mmol / l）/高密度脂蛋白胆固醇（mmol / l）]计算。在ABCA1单核苷酸多态性（SNP）rs41429263和rs2020927中比较了罗格列酮对AIP改变的影响。结果：调整前，rs4149263基因型在12周时AIP的变化显着不同[TT的中位数（四分位间距）：-0.05（-0.21，0.09）; TC为0.02（-0.09，0.17）; CC为0.11（0.03，0.25）; P = 0.003]，但不在rs2020927 [TT的-0.04（-0.18，0.10）之间; TC为0.03（-0.17，0.15）; CC为-0.03（-0.13，0.10）; P ＝ 0.401]。在控制了年龄，性别和糖尿病持续时间之后，C等位基因的存在与AIP增加0.13显着相关[95％置信区间（CI），0.04-0.21; P = 0.003]。当另外控制体重指数和预处理代谢参数时，这种关联性没有显着变化（AIP的变化：0.14; 95％CI，0.04-0.24; P = 0.007）。结论：ABCA1 SNP rs4149263可能与罗格列酮治疗的2型糖尿病的动脉粥样硬化脂质谱改变有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号